Riccardo Dolcetti

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

Martina Proctor, Jazmina L Gonzalez Cruz, Sheena M Daignault-Mill, Margaret Veitch, Bijun Zeng, Anna Ehmann, Muhammed Sabdia, Cameron Snell, Colm Keane, Riccardo Dolcetti, Nikolas K Haass, James W Wells, Brian Gabrielli

Journal article  |  2021  |  CANCERS

Drugs selectively targeting replication stress have demonstrated significant preclinical activity, but this has not yet translated..

Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches

M James Lonie, P Andrew Barbour, Riccardo Dolcetti

Journal article  |  2021  |  CANCER TREATMENT REVIEWS

With an incidence that is constantly rising, oesophageal adenocarcinoma (OAC) is becoming an increasing health burden worldwide. A..

Abstract 272: Glycomics: Protein glycosylation changes in the pathogenesis of head and neck cancer

Mohammad Rasheduzzaman, Xi Zhang, Riccardo Dolcetti, Liz Kenny, Newell W Johnson, Daniel Kolarich, Chamindie Punyadeera

Conference Proceedings  |  2021  |  Cancer Chemistry

Abstract 1443: CHKing melanoma: CHK1 inhibitor low dose hydroxyurea triggers immunogenic cell death and immunostimulatory cytokine expression to drive an anti-tumor immune response

Brian G Gabrielli, Martina Proctor, Jazmina Gonzalez Cruz, Bijun Zeng, Riccardo Dolcetti, Colm Keane, Nikolas Haass, James Wells

Conference Proceedings  |  2021  |  Experimental and Molecular Therapeutics

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing

Eric Alves, Shahama Taifour, Riccardo Dolcetti, Jonathan Chee, Anna K Nowak, Silvana Gaudieri, Pilar Blancafort

Journal article  |  2021  |  MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT

Precise clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genetic and epigenetic manipulation of the imm..

Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases

Priyakshi Kalita-de Croft, Haarika Chittoory, Tam H Nguyen, Jodi M Saunus, Woo Gyeong Kim, Amy E McCart Reed, Malcolm Lim, Xavier M De Luca, Kaltin Ferguson, Colleen Niland, Roberta Mazzieri, Riccardo Dolcetti, Peter T Simpson, Sunil R Lakhani

Journal article  |  2021  |  BIOLOGY-BASEL

The heterogeneity of tumor infiltrating lymphocytes (TILs) is not well characterized in brain metastasis. To address this, we perf..

PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases

Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Stefania Zanussi, Ombretta Repetto, Laura Gragnani, Francesca Maria Rossi, Riccardo Dolcetti, Anna Linda Zignego, Franco M Buonaguro, Agostino Steffan

Journal article  |  2021  |  LIVER INTERNATIONAL

BACKGROUND: Genetic variants of IFNL4 and PDCD1 genes have been shown to influence the spontaneous clearance of hepatitis C virus ..

Protein glycosylation in head and neck cancers: From diagnosis to treatment

Mohammad Rasheduzzaman, Arutha Kulasinghe, Riccardo Dolcetti, Liz Kenny, Newell W Johnson, Daniel Kolarich, Chamindie Punyadeera

Journal article  |  2020  |  BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Glycosylation is the most common post-translational modification (PTM) of proteins. Malignant tumour cells frequently undergo an a..

Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?

Hui Yi Chew, Victor Chan, Fiona Simpson, Riccardo Dolcetti

Journal article  |  2020  |  CANCERS

Sarcomas are a rare type of a heterogeneous group of tumours arising from mesenchymal cells that form connective tissues. Surgery ..

B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation

Cinzia Giagulli, Francesca Caccuri, Simone Zorzan, Antonella Bugatti, Alberto Zani, Federica Filippini, Ekta Manocha, Pasqualina D'Ursi, Alessandro Orro, Riccardo Dolcetti, Arnaldo Caruso

Journal article  |  2020  |  CANCER GENE THERAPY

Combined antiretroviral therapy (cART) for HIV-1 dramatically slows disease progression among HIV+ individuals. Currently, lymphom..